Removable Biodegradable Implant for Sustained TMC278 Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current NNRTI therapies for HIV require frequent and strict adherence, leading to challenges in maintaining effective drug plasma levels and are associated with side effects, while long-acting formulations may not be easily removable in case of adverse reactions.
Innovation Solution
An implantable device comprising a biocompatible, biodegradable polymer mixed with TMC278 and release-enhancing agents such as poloxamers, polysorbates, and DMSO/PVP, which allows for sustained release of TMC278 with immediate onset and the option to be removed if necessary, reducing pill burden and improving adherence.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If long-acting parenteral formulations of TMC278 are used to maintain effective drug plasma levels for long periods, then adherence requirements are reduced and viral suppression is improved, but the formulations cannot be easily retrieved if adverse reactions occur
Solution Approach 1:
The implantable device is designed as a removable implant that can be easily extracted from the patient's body if adverse reactions occur. The device contains a biodegradable polymer matrix with embedded TMC278 and release-enhancing agents, providing long-acting therapy (months) while maintaining removability. This resolves the contradiction by offering long duration of action through sustained release mechanisms while preserving the ability to remove the device if needed, unlike irreversible parenteral formulations.
2Reliability
If oral NNRTI therapies are administered frequently to maintain effective plasma levels, then viral suppression can be achieved, but adherence becomes extremely difficult to maintain over a lifetime
Solution Approach 1:
The invention segments the drug delivery into a single implantable device that releases TMC278 continuously over months, replacing the need for daily oral dosing. The device contains a polymer matrix segmented with release-enhancing agents (poloxamers, polysorbates, DMSO/PVP) that control drug release. This segmentation approach maintains reliable viral suppression while dramatically improving ease of operation by eliminating frequent dosing requirements.
Solution Approach 2:
The implantable device provides continuous release of TMC278 at steady levels over an extended period (months), ensuring uninterrupted therapeutic effect. The sustained release mechanism maintains effective plasma concentrations without the peaks and troughs associated with intermittent oral dosing. This continuity ensures reliable viral suppression while improving adherence by requiring only a single implantation procedure rather than lifelong daily compliance.
3Reliability
If the concentration of TMC278 in plasma is maintained at optimal levels through regular dosing, then resistance development is prevented, but the dosing regimen becomes increasingly complex and burdensome
Solution Approach 1:
The implantable device ensures continuous maintenance of optimal TMC278 plasma concentrations through controlled sustained release, preventing the sub-optimal levels that lead to resistance development. The device eliminates dosing intervals that would otherwise create vulnerability windows for resistance emergence. This continuous action simplifies the regimen from complex multiple daily doses to a single implantation, maintaining reliable resistance prevention while reducing regimen complexity.
Solution Approach 2:
The invention changes the delivery parameters from intermittent high-concentration pulses (oral dosing) to continuous low-to-moderate concentration release (implant). This parameter change maintains plasma levels within the optimal therapeutic window continuously, preventing resistance development. The sustained release mechanism, enhanced by poloxamers/polysorbates/DMSO-PVP, achieves this parameter optimization while simplifying the overall treatment approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The device provides steady and prolonged effective blood plasma levels of TMC278, reducing the risk of resistance and side effects, while allowing for easy removal in case of adverse reactions, thus enhancing patient compliance and safety.
Implementation Method 1
the body fluids to penetrate the implant
Implementation Method 2
biocompatible, biodegradable polymer
Implementation Method 3
addition of specific agents overcomes this initial drop in the release of TMC278 from the implant
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to an implantable device comprising a biocompatible, biodegradable polymer mixed with TMC278 and with one or more release-enhancing agents selected from the group consisting of poloxamers, polysorbates, and a combination of dimethyl sulfoxide (DMSO) and poly( vinyl pyrrolidone)(PVP).